Ecully, October 14, 2025 – 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465<td s ...

Company Overview - Spineway designs, manufactures, and markets innovative implants and surgical instruments for treating severe disorders of the spinal column [8] - The company has an international network of over 50 independent distributors, with 70% of its revenue coming from exports [8] General Meeting Highlights - The Combined General Meeting of Spineway shareholders was held on June 4, 2025, with 34,383,058 shares represented, accounting for 100% of voting rights [4] - Resolutions 1, 2, 3, 4, 6, 7, 8, 14, 15, 20, and 21 were approved, while resolutions 5, 9, 10, 11, 12, 13, 16, 17, 18, and 19 were rejected [5] Upcoming Events - The next significant date for the company is July 30, 2025, when half-year sales for 2025 will be reported [6] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), indicating its compliance with certain regulatory frameworks [7]

Company Information - Spineway is engaged in the design, manufacture, and marketing of innovative implants and surgical instruments for treating severe spinal disorders [7] - The company has an international network of over 50 independent distributors, with more than 70% of its revenue generated from exports [7] Upcoming Events - A Combined General Meeting is scheduled for June 4, 2025, at 2:00 p.m. at the Group's headquarters in Ecully [3] - The notice of the meeting, including the agenda and resolutions, was published on April 30, 2025 [4] - The next financial report, detailing H1 2025 revenue, is expected on July 30, 2025 [5] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), which may attract certain investors [6] - All preparatory documents for the General Meeting can be accessed on the company's website under "Investors/Regulated Information" [5]